An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype

Epithelial-mesenchymal transition (EMT), a mechanism important for embryonic development, plays a critical role during malignant transformation. While much is known about transcriptional regulation of EMT, alternative splicing of several genes has also been correlated with EMT progression, but the extent of splicing changes and their contributions to the morphological conversion accompanying EMT have not been investigated comprehensively. Using an established cell culture model and RNA–Seq analyses, we determined an alternative splicing signature for EMT. Genes encoding key drivers of EMT–dependent changes in cell phenotype, such as actin cytoskeleton remodeling, regulation of cell–cell junction formation, and regulation of cell migration, were enriched among EMT–associated alternatively splicing events. Our analysis suggested that most EMT–associated alternative splicing events are regulated by one or more members of the RBFOX, MBNL, CELF, hnRNP, or ESRP classes of splicing factors. The EMT alternative splicing signature was confirmed in human breast cancer cell lines, which could be classified into basal and luminal subtypes based exclusively on their EMT–associated splicing pattern. Expression of EMT–associated alternative mRNA transcripts was also observed in primary breast cancer samples, indicating that EMT–dependent splicing changes occur commonly in human tumors. The functional significance of EMT–associated alternative splicing was tested by expression of the epithelial-specific splicing factor ESRP1 or by depletion of RBFOX2 in mesenchymal cells, both of which elicited significant changes in cell morphology and motility towards an epithelial phenotype, suggesting that splicing regulation alone can drive critical aspects of EMT–associated phenotypic changes. The molecular description obtained here may aid in the development of new diagnostic and prognostic markers for analysis of breast cancer progression.

[1]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[2]  Stuart Thomson,et al.  A systems view of epithelial–mesenchymal transition signaling states , 2010, Clinical & Experimental Metastasis.

[3]  Yi Xing,et al.  An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition , 2010, The EMBO journal.

[4]  C. Ghigna,et al.  Sam68 regulates EMT through alternative splicing–activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene , 2010, The Journal of cell biology.

[5]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[6]  Lior Pachter,et al.  Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer , 2010, Molecular Cancer Research.

[7]  A. Ladd,et al.  Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity , 2010, RNA biology.

[8]  Gene W. Yeo,et al.  Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. , 2009, Molecular cell.

[9]  Claude C. Warzecha,et al.  The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events , 2009, RNA biology.

[10]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[11]  Y. Kaneda,et al.  Zyxin mediates actin fiber reorganization in epithelial-mesenchymal transition and contributes to endocardial morphogenesis. , 2009, Molecular biology of the cell.

[12]  Walter Hunziker,et al.  Vimentin regulates scribble activity by protecting it from proteasomal degradation. , 2009, Molecular biology of the cell.

[13]  Sherif Abou Elela,et al.  Cancer-associated regulation of alternative splicing , 2009, Nature Structural &Molecular Biology.

[14]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[15]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[16]  John S. Condeelis,et al.  Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination , 2009, Clinical Cancer Research.

[17]  Gene W. Yeo,et al.  An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells , 2009, Nature Structural &Molecular Biology.

[18]  J. Klijn,et al.  Low-risk susceptibility alleles in 40 human breast cancer cell lines , 2009, BMC Cancer.

[19]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[20]  T. Meyer,et al.  Modular control of endothelial sheet migration. , 2008, Genes & development.

[21]  Sherif Abou Elela,et al.  Identification of alternative splicing markers for breast cancer. , 2008, Cancer research.

[22]  B. Olsen,et al.  Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. , 2008, Molecular biology of the cell.

[23]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[24]  Tiffany W Guo,et al.  Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. , 2008, Molecular biology of the cell.

[25]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  U. Philippar,et al.  Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines , 2008, Clinical Cancer Research.

[27]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[28]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[29]  P. Febbo,et al.  Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo , 2008, Clinical & Experimental Metastasis.

[30]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[31]  M. Waltham,et al.  Epithelial mesenchymal transition traits in human breast cancer cell lines , 2008, Clinical & Experimental Metastasis.

[32]  Andrew J Ewald,et al.  Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. , 2008, Developmental cell.

[33]  W. Nelson,et al.  Regulation of cell-cell adhesion by the cadherin-catenin complex. , 2008, Biochemical Society transactions.

[34]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[35]  J. Clements,et al.  Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression , 2007, Journal of cellular physiology.

[36]  Alan Wells,et al.  EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation , 2007, Journal of Cell Science.

[37]  H. Kajiyama,et al.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. , 2007, International journal of oncology.

[38]  Alicia Zhou,et al.  Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers , 2007, Proceedings of the National Academy of Sciences.

[39]  M. Pajares,et al.  Alternative splicing: an emerging topic in molecular and clinical oncology. , 2007, The Lancet. Oncology.

[40]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[41]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[42]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[43]  J. Thierry-Mieg,et al.  AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.

[44]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[45]  B. Blencowe.  Alternative Splicing: New Insights from Global Analyses , 2006, Cell.

[46]  M. Swanson,et al.  Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. , 2006, Human molecular genetics.

[47]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[48]  G. Christofori.  New signals from the invasive front , 2006, Nature.

[49]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[50]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[51]  B. Gumbiner,et al.  The mammalian Scribble polarity protein regulates epithelial cell adhesion and migration through E-cadherin , 2005, The Journal of cell biology.

[52]  E. Hay,et al.  Microarray analysis of gene expression during epithelial–mesenchymal transformation , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[53]  D. Tarin,et al.  Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? , 2005, Cancer research.

[54]  Keith Baggerly,et al.  Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression , 2004, Breast Cancer Research.

[55]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[56]  J. Gutkind,et al.  Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential , 2004, Oncogene.

[57]  Anne Vincent-Salomon,et al.  Epithelial–mesenchymal transition in breast cancer development , 2003 .

[58]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.

[59]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[62]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[63]  M. Troxell,et al.  Inhibiting cadherin function by dominant mutant E-cadherin expression increases the extent of tight junction assembly. , 2000, Journal of cell science.

[64]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  S. Hellman,et al.  Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  F. van Roy,et al.  Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. , 1998, Genomics.

[67]  J. Claverie,et al.  The significance of digital gene expression profiles. , 1997, Genome research.

[68]  M. Balda,et al.  Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical- basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein , 1996, The Journal of cell biology.

[69]  H. Peterse,et al.  Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[70]  J. Thiery,et al.  Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. , 1994, Molecular biology of the cell.

[71]  B. Thisse,et al.  The twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. , 1987, Nucleic acids research.